White House Boosts At-Home COVID-19 Test Production
This week, the White House announced the purchase of 8.5 million rapid at-home COVID-19 tests that can be taken without a prescription. Recall, the U.S. Food and Drug Administration (FDA) issued an EUA to Ellume in December 2020 for its at-home rapid COVID-19 test.
The Biden-Harris Administration this week indicated it reached a $231.8 million agreement with Ellume to quickly scale up its production and create a manufacturing facility within the U.S. The expansion of the at-home COVID-19 tests is anticipated to provide for 640,000 tests per day by December 2021 to support domestic COVID-19 testing.
A full press announcement on the production expansion is available here.